An agreement has been reached in the USA between the pharmaceuticals group of ICI Americas and Miles, the US subsidiary of Germany's Bayer AG, to copromote the antibiotic Cipro (ciprofloxacin). The move means that, starting in the fall, Miles' existing 1,200-strong sales force will be backed up with an additional 400 people from ICI Pharmaceuticals Group of Wilmington, Delaware.
Ciprofloxacin was first launched in the USA by Miles in 1987, and since then it has become the leading quinolone antibiotic and one of the most frequently prescribed drugs in the country. In 1991, sales of the tablet formulation exceeded $470 million, according to ICI.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze